1. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. (November 2021) Authors: Socinski, Mark A.; Waller, Cornelius F.; Idris, Tazeen; Bondarenko, Igor; Luft, Alexander; Beckmann, Katrin; Vishweswaramurthy, Ashwini; Loganathan, Subramanian; Donnelly, Charles; Hummel, Matthew A.; Shapiro, Roxann; Woods, Melody; Rao, Anita; Nayak, Vivek G; Ranganna, Gopinath; Barve, Abhijit Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗